Claims for Patent: 9,132,168

Summary for Patent: 9,132,168

Title:	Methods of treating cognitive impairment
Abstract:	The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.
Inventor(s):	Potter; Huntington (Tampa, FL), Boyd; Timothy (Seffner, FL), Jim; Heather Sevey Lawrence (Tampa, FL)
Assignee:	UNIVERSITY OF SOUTH FLORIDA (Tampa, FL) H. LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTE, INC. (Tampa, FL)
Application Number:	13/165,344
Patent Claims:	1. A method for improving cognition in a person or animal receiving or that has received chemotherapy or radiation exposure or treatment for the treatment of cancer, wherein improvements in cognition are characterized by improvements in memory, attention, concentration, and/or executive function, said method comprising administering to the person or animal that is receiving or that has received chemotherapy or radiation exposure or treatment for the treatment of cancer an effective amount of combination of both granulocyte/macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF), or a composition comprising combination of both GM-CSF and G-CSF. 2. The method of claim 1, wherein said GM-CSF and G-CSF are administered intracranially. 3. The method of claim 1, wherein said GM-CSF and G-CSF are administered by intracranial infusion. 4. The method of claim 1, wherein said method further comprises evaluating the person or animal for cognitive function prior to treatment. 5. The method of claim 1, wherein said composition comprises a pharmaceutically acceptable carrier, diluent, or solute. 6. The method of claim 1, wherein said method further comprises administering Darbepoetin and/or erythropoietin (EPO) to the person or animal. 7. The method of claim 1, wherein said GM-CSF is sargramostim. 8. The method of claim 1, where said GM-CSF is human GM-CSF. 9. The method of claim 1, wherein the cancer is multiple myeloma or non-Hodgkin's lymphoma. 10. The method of claim 1, wherein said GM-CSF and G-CSF are administered orally, intravenously, intramuscularly, intraperitoneally, subcutaneously, or intranasally. 11. The method of claim 1, wherein the cancer is acute myelogenous leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, breast carcinoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, myeloproliferative neoplasm, Hodgkin's lymphoma, or aplastic anemia. 12. The method of claim 1, wherein said G-CSF is human G-CSF. 13. The method of claim 1, wherein said G-CSF is filgrastim or pegfilgrastim.

Details for Patent 9,132,168

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	NEUPOGEN	filgrastim	Injection	103353	02/20/1991		2028-08-05
Amgen, Inc.	NEUPOGEN	filgrastim	Injection	103353	06/28/2000		2028-08-05
Partner Therapeutics, Inc.	LEUKINE	sargramostim	For Injection	103362	03/05/1991		2028-08-05
Partner Therapeutics, Inc.	LEUKINE	sargramostim	Injection	103362	03/05/1991		2028-08-05